Since combination therapy significantly improved CD4+ non-Treg/Treg and CD8+/Treg ratios as compared to α-CTLA-4 or α-PD-1 monotherapy in tumours (Fig. 3c,d), we reasoned that combination therapy could more potently stimulate effector functions of TILs. The gene discussed is CD8A; the disease is neoplasm.